Loading…
Amanta Healthcare (AMANTA)₹202.15−0.50%Pharmaceuticals
In the Jun 2026 quarter (standalone), Amanta Healthcare reported sales of ₹68.98 Cr, up 5.3% from Jun 2025, and net profit of ₹3.30 Cr, down 5.7% year on year. For the year to Mar 2026, sales were ₹289 Cr and net profit ₹14.99 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 68.27 | 66.95 | 68.02 | 72.33 | 65.52 | 71.09 | 74.73 | 77.21 | 68.98 |
| Expenses | 54.84 | 52.94 | 52.83 | 53.20 | 50.50 | 56.37 | 59.20 | 62.17 | 54.38 |
| Operating Profit | 13.43 | 13.91 | 15.10 | 19.00 | 14.93 | 14.69 | 15.40 | 14.99 | 14.57 |
| OPM % | 19.7% | 20.8% | 22.2% | 26.3% | 22.8% | 20.7% | 20.6% | 19.5% | 21.2% |
| Other Income | 0.14 | 0.20 | 0.86 | 0.15 | 0.95 | −2.55 | 0.67 | 1.65 | 0.63 |
| Interest | 9.43 | 6.30 | 5.88 | 6.27 | 6.28 | 5.14 | 5.05 | 4.24 | 5.99 |
| Depreciation | 4.61 | 4.61 | 4.52 | 4.70 | 4.65 | 4.65 | 4.66 | 4.74 | 4.70 |
| Profit before tax | −0.51 | 3.18 | 5.53 | 8.17 | 4.94 | 2.29 | 6.33 | 7.64 | 4.50 |
| Tax % | −28.0% | 28.7% | 22.6% | 26.9% | 28.8% | 46.9% | 26.5% | 27.4% | 26.3% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −0.65 | 0.00 | 0.00 | 0.00 |
| Net Profit | −0.35 | 2.25 | 4.27 | 5.95 | 3.50 | 1.20 | 4.62 | 5.52 | 3.30 |
| EPS (Rs) | −0.12 | 0.77 | 1.47 | 2.06 | 1.21 | 0.30 | 1.18 | 1.41 | 0.84 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 184 | 171 | 226 | 260 | 281 | 276 | 289 | 292 |
| Expenses | 147 | 133 | 173 | 206 | 223 | 215 | 229 | 232 |
| Operating Profit | 37.05 | 38.05 | 52.10 | 53.14 | 58.14 | 60.11 | 60.10 | 59.65 |
| OPM % | 20.0% | 22.0% | 23.0% | 20.0% | 21.0% | 22.0% | 21.0% | 20.4% |
| Other Income | 1.99 | 0.99 | 75.76 | 3.99 | 0.99 | 0.99 | 0.99 | 0.40 |
| Interest | 37.91 | 39.89 | 48.89 | 34.90 | 33.91 | 27.95 | 20.95 | 20.42 |
| Depreciation | 16.01 | 16.99 | 17.01 | 17.99 | 19.99 | 18.01 | 18.99 | 18.75 |
| Profit before tax | −15.04 | −18.03 | 62.12 | 3.01 | 5.01 | 15.04 | 21.05 | 20.76 |
| Tax % | 25.0% | 23.0% | 11.0% | 179.0% | 32.0% | 29.0% | 30.0% | — |
| Exceptional items | 0.00 | 0.00 | 67.88 | 0.00 | 0.00 | 0.00 | −1.99 | −0.65 |
| Net Profit | −18.99 | −21.99 | 54.91 | −1.99 | 3.99 | 9.99 | 14.99 | 14.64 |
| EPS (Rs) | −7.01 | −8.11 | 20.47 | −0.78 | 1.34 | 3.63 | 3.82 | 3.73 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 27.07 | 27.05 | 27.07 | 27.04 | 27.04 | 29.03 | 39.01 |
| Reserves | 2.01 | −20.02 | 36.04 | 35.99 | 39.04 | 67.98 | 181 |
| Borrowings | 231 | 235 | 226 | 216 | 211 | 204 | 243 |
| Other Liabilities | 127 | 150 | 104 | 95.54 | 74.79 | 80.62 | 92.56 |
| Total Liabilities | 387 | 391 | 392 | 373 | 352 | 381 | 557 |
| Fixed Assets | 244 | 242 | 240 | 232 | 228 | 217 | 207 |
| CWIP | 0.00 | 0.00 | 0.00 | 8.98 | 0.00 | 6.99 | 81.91 |
| Investments | 0.00 | 1.99 | 3.01 | 0.00 | 3.99 | 7.99 | 7.01 |
| Other Assets | 144 | 149 | 149 | 133 | 120 | 149 | 261 |
| Inventories | 39.16 | 57.22 | 71.21 | 69.26 | 59.21 | 73.27 | 83.34 |
| Trade receivables | 52.02 | 51.01 | 45.05 | 54.09 | 48.02 | 50.08 | 43.03 |
| Cash & equivalents | 6.01 | 8.99 | 10.01 | 3.99 | 4.01 | 3.01 | 93.04 |
| Total Assets | 387 | 391 | 392 | 373 | 352 | 381 | 557 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 37.98 | 31.01 | 61.95 | 42.99 | 58.01 | 47.01 | 48.01 |
| Cash from investing activity | −8.99 | −12.99 | −5.99 | −6.99 | −9.99 | −23.99 | −93.87 |
| Cash from financing activity | −36.99 | −18.01 | −50.01 | −42.01 | −46.02 | −22.99 | 126 |
| Net cash flow | −7.98 | 0.00 | 5.99 | −5.98 | 0.99 | −0.99 | 80.85 |
| Capex | 10.96 | 12.95 | 9.96 | 5.98 | 12.96 | 20.93 | 79.71 |
| Free cash flow | 27.06 | 19.05 | 52.09 | 36.10 | 46.14 | 26.04 | −32.07 |
| CFO / OP % | 102.0% | 66.0% | 119.0% | 93.0% | 111.0% | 84.0% | 93.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 104 | 110 | 73 | 75 | 63 | 67 | 55 |
| Inventory days | 224 | 421 | 337 | 246 | 308 | 463 | 311 |
| Days payable | 100 | 187 | 186 | 131 | 130 | 195 | 137 |
| Cash conversion cycle | 229 | 345 | 226 | 193 | 243 | 336 | 231 |
| Working capital days | 50 | −6 | 27 | 41 | 15 | 25 | 5 |
| ROCE % | — | 9.0% | 14.0% | 13.0% | 14.0% | 15.0% | 12.0% |
For the Jun 2026 quarter, Amanta Healthcare reported sales of ₹68.98 Cr, up 5.3% year on year and net profit of ₹3.30 Cr, down 5.7% year on year. The operating margin was 21.2%.
Amanta Healthcare's sales for the year to Mar 2026 were ₹289 Cr; over the last twelve months they were ₹292 Cr.
Net profit for the year to Mar 2026 was ₹14.99 Cr, and ₹14.64 Cr over the last twelve months. Earnings per share over the same trailing period were ₹3.73.
Amanta Healthcare reported borrowings of ₹243 Cr at Mar 2026, against cash and equivalents of ₹93.04 Cr.
Cash from operations was ₹48.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹32.07 Cr.